miRNAs and lncRNAs as predictive biomarkers of response to FOLFOX therapy in colorectal cancer

Research output: Contribution to journalShort survey

8 Citations (Scopus)

Abstract

Chemotherapy is one of the options for cancer treatment. FOLFOX is one of the widely used chemotherapeutic regimens used to treat primarily colorectal cancer and other cancers as well. However, the emergence of chemo-resistance clones during cancer treatment has become a critical challenge in the clinical setting. It is crucial to identify the potential biomarkers and therapeutics targets which could lead to an improvement in the success rate of the proposed therapies. Since non-coding RNAs have been known to be important players in the cellular system, the interest in their functional roles has intensified. Non-coding RNAs (ncRNAs) as regulators at the post-transcriptional level could be very promising to provide insights in overcoming chemo-resistance to FOLFOX. Hence, this mini review attempts to summarize the potential of ncRNAs correlating with chemo-sensitivity/resistance to FOLFOX.

Original languageEnglish
Article number846
JournalFrontiers in Pharmacology
Volume9
Issue numberAUG
DOIs
Publication statusPublished - 6 Aug 2018

Fingerprint

Long Noncoding RNA
MicroRNAs
Untranslated RNA
Colorectal Neoplasms
Biomarkers
Neoplasms
Therapeutics
Clone Cells
Drug Therapy

Keywords

  • Biomarkers
  • Chemo-resistance
  • FOLFOX
  • Molecular target
  • Non-coding RNAs

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{df3eb2d6e30a4b87b0379a60aa2c85db,
title = "miRNAs and lncRNAs as predictive biomarkers of response to FOLFOX therapy in colorectal cancer",
abstract = "Chemotherapy is one of the options for cancer treatment. FOLFOX is one of the widely used chemotherapeutic regimens used to treat primarily colorectal cancer and other cancers as well. However, the emergence of chemo-resistance clones during cancer treatment has become a critical challenge in the clinical setting. It is crucial to identify the potential biomarkers and therapeutics targets which could lead to an improvement in the success rate of the proposed therapies. Since non-coding RNAs have been known to be important players in the cellular system, the interest in their functional roles has intensified. Non-coding RNAs (ncRNAs) as regulators at the post-transcriptional level could be very promising to provide insights in overcoming chemo-resistance to FOLFOX. Hence, this mini review attempts to summarize the potential of ncRNAs correlating with chemo-sensitivity/resistance to FOLFOX.",
keywords = "Biomarkers, Chemo-resistance, FOLFOX, Molecular target, Non-coding RNAs",
author = "Hon, {Kha Wai} and Nadiah Abu and {Ab Mutalib}, {Nurul Syakima} and {A. Jamal}, {A. Rahman}",
year = "2018",
month = "8",
day = "6",
doi = "10.3389/fphar.2018.00846",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - miRNAs and lncRNAs as predictive biomarkers of response to FOLFOX therapy in colorectal cancer

AU - Hon, Kha Wai

AU - Abu, Nadiah

AU - Ab Mutalib, Nurul Syakima

AU - A. Jamal, A. Rahman

PY - 2018/8/6

Y1 - 2018/8/6

N2 - Chemotherapy is one of the options for cancer treatment. FOLFOX is one of the widely used chemotherapeutic regimens used to treat primarily colorectal cancer and other cancers as well. However, the emergence of chemo-resistance clones during cancer treatment has become a critical challenge in the clinical setting. It is crucial to identify the potential biomarkers and therapeutics targets which could lead to an improvement in the success rate of the proposed therapies. Since non-coding RNAs have been known to be important players in the cellular system, the interest in their functional roles has intensified. Non-coding RNAs (ncRNAs) as regulators at the post-transcriptional level could be very promising to provide insights in overcoming chemo-resistance to FOLFOX. Hence, this mini review attempts to summarize the potential of ncRNAs correlating with chemo-sensitivity/resistance to FOLFOX.

AB - Chemotherapy is one of the options for cancer treatment. FOLFOX is one of the widely used chemotherapeutic regimens used to treat primarily colorectal cancer and other cancers as well. However, the emergence of chemo-resistance clones during cancer treatment has become a critical challenge in the clinical setting. It is crucial to identify the potential biomarkers and therapeutics targets which could lead to an improvement in the success rate of the proposed therapies. Since non-coding RNAs have been known to be important players in the cellular system, the interest in their functional roles has intensified. Non-coding RNAs (ncRNAs) as regulators at the post-transcriptional level could be very promising to provide insights in overcoming chemo-resistance to FOLFOX. Hence, this mini review attempts to summarize the potential of ncRNAs correlating with chemo-sensitivity/resistance to FOLFOX.

KW - Biomarkers

KW - Chemo-resistance

KW - FOLFOX

KW - Molecular target

KW - Non-coding RNAs

UR - http://www.scopus.com/inward/record.url?scp=85054932271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054932271&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00846

DO - 10.3389/fphar.2018.00846

M3 - Short survey

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - AUG

M1 - 846

ER -